

Serial No.: 10/549,323

Atty. Docket No.: LNK-007

Rule 312 Amendment of August 12, 2009

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Previously Presented) A method of reducing a lesion of cerebral tissue induced by cerebral ischemia, wherein the cerebral ischemia occurs as a result of apoplexy, said method comprising the steps of administering to a subject in need thereof a medicament comprising a neuroprotective amount of a hydrogenation product obtained through the catalytic hydrogenation of an ethanol extract of frankincense (*Boswellia serrata*).
2. (Canceled)
3. (Canceled)
4. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises one or more compounds selected from the group consisting of a keto-boswellic acid, 3-O-acetyl-11-keto- β -boswellic acid, 11-keto- β -boswellic acid, a physiologically acceptable salt of a keto-boswellic acid, a derivative of a keto-boswellic acid, and a salt of a keto-boswellic acid derivative.
5. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises a tirucallic acid, another triterpene or a salt or derivative thereof.
6. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises an extract from *Boswellia serrata* resin.
7. (Previously Presented) A method of reducing a lesion of cerebral tissue induced by a cranial/brain trauma or a short-term cerebral ischemia resulting from apoplexy or cardiac infarction, said method comprising the steps of administering to a subject in need thereof

Serial No.: 10/549,323

Atty. Docket No.: LNK-007

Rule 312 Amendment of August 12, 2009

a medicament comprising a neuroprotective amount of a hydrogenation product of a frankincense extract or a physiologically acceptable salt of said hydrogenation product.

8. (Canceled)
9. (Canceled)
10. (Currently Amended) The method according to claim 7, wherein the ~~active ingredient comprises a hydrogenated product of a frankincense extract~~ comprises an extract obtained from Boswellia serrata resin.
11. (Canceled).
12. (Canceled).
13. (Canceled).
14. (Canceled).
15. (Canceled)
16. (Previously Presented) The method according to claim 1, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal, or intracranial administration.
17. (Previously Presented) The method according to claim 1, wherein the medicament comprises a tablet or solution.
18. (Previously Presented) The method according to claim 7, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal, or intracranial administration.
19. (Previously Presented) The method according to claim 7, wherein the medicament comprises a tablet or solution.